Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation

(2020) Huaxia Yang et al.   CLINICAL IMMUNOLOGY

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Evolution of Systemic Therapy for Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   HEPATOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

(2020) David J. Pinato et al.   Cancers

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

(2020) Petros Fessas et al.   Journal for ImmunoTherapy of Cancer

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

(2019) V. Ellen Maher et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic Treatment Options in Hepatocellular Carcinoma

(2019) Lorenza Rimassa et al.   Liver Cancer

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

(2019) Petros Fessas et al.   IMMUNOLOGY

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

(2019) Alessio Cortellini et al.   SEMINARS IN ONCOLOGY

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

(2018) Jordi Rimola et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

(2018) Koichi Sato et al.   LUNG CANCER

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

(2018) Aaron Lisberg et al.   Cancer Immunology Research

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy

(2018) Amber J. Giles et al.   Journal for ImmunoTherapy of Cancer

Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma

(2018) Michael J Flynn et al.   HEPATOLOGY

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

(2018) Biagio Ricciuti et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

(2018) Alice Indini et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

(2018) Yukihiro Toi et al.   JAMA Oncology

AASLD guidelines for the treatment of hepatocellular carcinoma

(2017) Julie K. Heimbach et al.   HEPATOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1

(2017) Anthousa Kythreotou et al.   JOURNAL OF CLINICAL PATHOLOGY

Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity

(2017) Alessandro Inno et al.   TUMORI

Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity

(2017) Alessandro Inno et al.   TUMORI JOURNAL

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

(2016) Julien Calderaro et al.   HEPATOLOGY

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER